LLPC working group

Composition 

Chair

Prof. M.J. Kersten (AmsterdamUMC – AMC, Amsterdam)

Vice-Chair

Prof. M.C. Minnema (UMC Utrecht, Utrecht)

Secretary

Dr P. Mutsaers (ErasmusMC, Rotterdam)

Key objectives of working group

The key objectives of this working group are:

• The objective of the consortium is to actively contribute to the implementation of so-called “first-in-man” / phase I-II studies in malignant diseases of the blood, bone marrow and lymph nodes. Initially, Non-Hodgkin's lymphoma (B and T cell), Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) were chosen. Promising new drugs can then be incorporated in phase III studies, which are placed in the HOVON Lymphoma and CLL Working Groups. This creates the perspective to operate in the front line in HOVON with regard to the treatment of lymphomas and CLL.
• Secondly, the accumulated expertise can be used to promote first-in-man trials / phase I-II studies in other hematological malignancies in collaboration with the respective HOVON Working Groups.
• For the time being, it is expected that there will mainly be industry-sponsored trials. Ultimately, the goal is also to develop investigator-initiated studies. The working group will assess the relevance and feasibility of each study offered through one of its members or by industry. If it is decided to participate in the study, it will be determined by mutual agreement how many and which centers will participate.

The Lunenburg Lymphoma Phase 1 / II Consortium (LLPC) was founded in 2009 by 5 departments of Hematology of Dutch (academic) hospitals. Currently, the participating hospitals are:

• Academic Medical Center (AmsterdamUMC - AMC), Amsterdam
• Free University Medical Center (AmsterdamUMC - VUMC), Amsterdam
• Erasmus Medical Center, Rotterdam
• University Medical Center Groningen (UMCG), Groningen
• University Medical Center Nijmegen (UMCN), Nijmegen
• University Medical Center Utrecht (UMCU), Utrecht
• St. Antonius Hospital, Nieuwegein
• Leiden University Medical Center (LUMC), Leiden
• Maastricht University Medical Center (MUMC), Maastricht

Publication overview

• Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study
• Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
• Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.
• Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
• European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
• Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. 
• Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. 
• Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.
• Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
• Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
• Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
• Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.

Meetings & Minutes

Please note the section where meetings dates & minutes are shown are only accessible after log in.